- Anxiety is implicated in several chronic physical illnesses including heart disease, respiratory disorders and gastrointestinal conditions
- Scientific evidence in several studies shows that CBD exhibits anti-inflammatory and anti-anxiety properties
- Newly created medicinal cannabis division will focus on development of cannabinoids as preventative treatment for anxiety disorders
- Use of PreveCeutical’s proprietary Sol-gel nasal delivery platform for cannabinoid therapy promises ease of use, sustained release, better efficacy
- Preventative medicine industry represents a $3.8 trillion market
Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is tackling a topic that many people hesitate to bring up – anxiety disorders, including the devastating physical and emotional damage they cause and the social stigma that’s often associated with them. PreveCeutical’s newly created medicinal cannabis division is bringing the subject out into the open with one goal in mind: to create an effective, preventive treatment that combines the company’s Sol-gel (“Sol-gel”) nasal delivery platform with the beneficial properties of cannabinoids, a news release states (http://nnw.fm/ldw3S).
Anxiety disorders are the most common mental illnesses in the U.S., affecting nearly 40 million adults age 18 and older, although only 37 percent are receiving treatment, according to the Anxiety and Depression Association of America (http://nnw.fm/jX4Qz). Similarly, the Anxiety Disorders Association of Canada claims that one in four Canadians will suffer from an anxiety disorder in their lifetime (http://nnw.fm/L4G4j). From generalized anxiety disorder, which manifests itself as an exaggerated worry about personal health or other aspects of daily life for six months or more, to irrational fears and phobias, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder and panic disorder, those diagnosed may also suffer with a concurrent physical illness that makes symptoms worse and recovery difficult.
Common treatments focus on drugs that may help but still produce significant and unpleasant side effects. Development of a subtly administered cannabidiol (“CBD”) product in a sustained low dose using PreveCeutical’s Sol-gel delivery method could provide relief for millions seeking an alternative therapy. As more states in the U.S. and Canada legalize cannabis for adult-use, there’s a similar growth in the public’s interest in CBD therapies, especially as a compound that can help relieve anxiety, National Public Radio reports (http://nnw.fm/yLI6R).
“I think there’s good evidence to suggest that CBD could be an effective treatment of anxiety and addiction” and other disorders, Dr. Esther Blessing, a psychiatrist and researcher at New York University, told NPR. “But we need clinical trials to find out.”
Though CBD is extracted from cannabis, unlike another cannabinoid, THC, it does not have psychoactive properties. In one widely reported CBD-use study, scholars at the University of Sao Paolo summarized a number of human and animal studies to conclude that the compound “promotes anti-anxiety effects in humans.” In another compilation of related studies, the effects of cannabinoids on patients with social anxiety disorder, fear of public speaking and paranoia showed a general beneficial effect, an article from the Harvard Kennedy School Shorenstein Center on Media, Politics and Public Policy states (http://nnw.fm/j9tLx).
The launch of PreveCeutical’s cannabis division puts the company on track to further its aim of becoming a leader in preventative health care by developing high quality, tailored medicinal cannabis-based products (http://nnw.fm/3qXh4). With Sol-gel’s innovative cannabidiol-based nose to brain delivery system, designed to give consumers relief from epileptic seizures, pain, inflammation, anxiety disorders and other neurological conditions, PreveCeutical will aim to reach its goal of helping consumers prevent ailments and live healthier, better lives.
For more information, visit the company’s website at www.PreveCeutical.com
More from NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com